Plain Language Summaries is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • How to
  • FAQs
  • Publications
  • Advisory Panel
    • Plain Language Advisors
    • Scientific Content Advisors
  • Supporters
  • Blog
  • About us
  • Contact Us

chemotherapy

Screenshot of first page of the PLSP
16th Apr 2026

A plain language summary looking at nivolumab + chemotherapy for Asian people with advanced/recurrent stomach or gastroesophageal cancer

28th Nov 2025

How alectinib performed against chemotherapy in ALINA study: a plain language summary

27th May 2025

Plain language summary: comparing encorafenib plus cetuximab with chemotherapy vs standard treatments for BRAF V600E-mutant metastatic colorectal cancer in the BREAKWATER study

25th Feb 2025

A plain language summary of the FLAURA2 study results: First-line osimertinib treatment with or without chemotherapy in patients with untreated EGFR-mutated advanced NSCLC

11th Feb 2025

A plain language summary of the EV-302/KEYNOTE-A39 study: evaluating the effectiveness and safety of enfortumab vedotin (EV) with pembrolizumab in advanced urothelial cancer

23rd Jan 2025

A plain language summary of the CheckMate 901 study: nivolumab combined with chemotherapy versus chemotherapy alone for advanced urothelial cancer

22nd Jan 2025

Avelumab maintenance treatment for advanced urothelial cancer: plain language summary of long-term results from the JAVELIN Bladder 100 study

22nd Jan 2025

Plain language summary of the DESTINY-Breast04 study: Trastuzumab deruxtecan for previously treated HER2-low advanced breast cancer

15th Nov 2024

The safety of relugolix combination therapy for advanced prostate cancer

28th Aug 2024

DESTINY-Lung01 Study: a plain language summary on Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer

25th Jul 2024

Plain Language Summary of amivantamab combined with chemotherapy in PAPILLON study for untreated EGFR-mutated non-small-cell lung cancer

Sacituzumab govitecan (brand name: TRODELVY®) is a new treatment being studied for people with a type of bladder cancer, called urothelial cancer, that has progressed to a locally advanced or metastatic stage. Locally advanced and metastatic urothelial cancer are usually treated with platinum-based chemotherapy. Metastatic urothelial cancer is also treated with immune checkpoint inhibitors. There are few treatment options for people whose cancer gets worse after receiving these treatments. Sacituzumab govitecan is a suitable treatment option for most people with urothelial cancer because it aims to deliver an anti-cancer drug directly to the cancer in an attempt to limit the potential harmful side effects on healthy cells. This is a summary of a clinical study called TROPHY-U-01, focusing on the first group of participants, referred to as Cohort 1. All participants in Cohort 1 received sacituzumab govitecan
30th Apr 2024

Sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancer- a plain language summary of the TROPHY-U-01 study

This is a summary of a publication about the DESTINY-Breast03 study, which was published in the New England Journal of Medicine in March 2022. The study included 524 adults with advanced breast cancer that is HER2-positive, which means it has high levels of a protein called HER2. All of the participants in this study had their cancer worsen after previously receiving treatment. The treatment that was previously given to participants was a combination of a drug called trastuzumab with a type of chemotherapy called a taxane. The researchers wanted to know whether a drug called trastuzumab deruxtecan (T-DXd) could improve participants’ cancer more than the standard treatment. The standard treatment is a drug called trastuzumab emtansine (T-DM1). The researchers looked at the results of this study before it was finished. This is a summary of those results.
22nd Jan 2024

The DESTINY-Breast03 study: a plain language summary comparing trastuzumab deruxtecan with trastuzumab emtansine for breast cancer

This is a summary of the publication about the DESTINY-Gastric01 study, which was published in the New England Journal of Medicine in May 2020. The study included 187 adults in Japan and South Korea with gastric cancer or gastroesophageal junction cancer that had high levels of a protein called HER2 (HER2-positive). All the participants’ cancer had spread to nearby or distant parts of the body and had worsened after receiving at least 2 previous cancer treatments or treatment combinations. The researchers wanted to know whether a drug called trastuzumab deruxtecan (T-DXd) could improve participants’ cancer more than standard chemotherapy drugs.
3rd Nov 2023

A plain language summary of the DESTINY-Gastric01 study: trastuzumab deruxtecan in previously treated HER2-positive gastric cancer

This is a summary describing the results of a Phase III study called TOPAZ-1. The study looked at treatment with durvalumab (a type of immunotherapy) and chemotherapy to treat participants with advanced biliary tract cancer (BTC). Advanced BTC is usually diagnosed at late stages of disease, when it cannot be cured by surgery. This study included participants with advanced BTC who had not received previous treatment, or had their cancer come back at least 6 months after receiving treatment or surgery that aimed to cure their disease. Participants received treatment with durvalumab and chemotherapy or placebo and chemotherapy. The aim of this study was to find out if treatment with durvalumab and chemotherapy could increase the length of time that participants with advanced BTC lived, compared with placebo and chemotherapy.
6th Oct 2023

The TOPAZ-1 study: a plain language summary describing durvalumab and chemotherapy for advanced biliary tract cancer

11th Apr 2023

Plain Language Summary: the CheckMate 649 study compares nivolumab in combination with chemotherapy with chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagus

Copyright © 2026 · Plain Language Summaries · Terms and conditions · Privacy policy · Cookie policy